Amicus Therapeutics — Technical Presentation (April 2019)
17 slides from Amicus Therapeutics's technical presentation, Apr 30, 2019
Slide 1: Preclinical Pompe Gene Therapy Results at ASGCT Conference Call & Webcast
Preclinical Pompe Gene Therapy Results at ASGCT Conference Call & Webcast April 30, 2019
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements This presentation contains "forward- looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to initial preclinical data from its investigational adeno-associated viral (AAV) gene therapy program for P
Slide 3: Pompe Disease Overview
Pompe Disease 3 Pompe Disease Overview Pompe Disease is a Fatal Neuromuscular and Motorneuron Disorder that Affects a Broad Range of People 5,000 – 10,000+ patients Respiratory and cardiac Age of onset ranges from infancy to diagnosed WW1; newborn failure are leading causes of morbidity adulthood sc
Slide 4: Amicus Gene Therapy Programs: Protein Engineering Expertise
Amicus Gene Therapy Programs 4 Amicus Protein Engineering Expertise & Technologies for Gene Therapy Collaboration to Enable Greater Protein Expression and Delivery at Lower Gene Therapy Doses Increased Increased Improved Protein Protein Protein Targeting & Expression Secretion Stabilization Novel un
Slide 5: Development of a Novel Gene Therapy for Pompe Disease
Development of a Novel Gene Therapy for Pompe Disease: Engineered Acid Alpha- Glucosidase Transgene for Improved Expression and Muscle Targeting American Society of Gene & Cell Therapy (ASGCT) 22nd Annual Meeting April 30, 2019
Slide 6: Initial High-Dose Preclinical POC Study
Preclinical Pompe Gene Therapy Results at ASGCT 6 AAV Gene Therapy Initial High-Dose Preclinical POC Study • AAV Transgene: AAV Expressing Trans-Gene Co nstructs – Natural-hGAA (AAV.hGAA nat) – Engineered-hGAA (AAV.hGAA eng) Native Signal Peptide Natural hGAA • Dose\Route: – 5e11 gc/mouse (~2.5e13 g
Slide 7: GAA Plasma Activity, Concentration and Cell-Surface Receptor Binding
Preclinical Pompe Gene Therapy Results at ASGCT 7 GAA Plasma Activity, Concentration and Cell-Surface Receptor Binding Binding to Intended Receptor Day 28 Plasma Samples used to evaluate receptor binding • Engineered hGAA was able to efficiently bind the • High levels of engineered and natural hGAA
Slide 8: Tibialis Anterior: Engineered hGAA More Efficient at Cross-Correction
Preclinical Pompe Gene Therapy Results at ASGCT 8 Tibialis Anterior – 28 days after AAV Gene Therapy Engineered hGAA was more Efficient at Cross-Correction as Indicated by Greater Cellular Uptake, Uniform Glycogen Reduction and Cell Pathology Correction Glycogen PAS - Tibialis anterior Vehicle AAV.h
Slide 9: Brain: Engineered hGAA Cross-Corrects at Low Levels
Preclinical Pompe Gene Therapy Results at ASGCT 9 Brain– 28 days after AAV Gene Therapy Engineered hGAA was able to Cross-Correct the Brain at Low Levels Due to Efficient Cellular Uptake while Natural hGAA was not able to Cross-Correct at Similar Expression Levels Glycogen Luxol/PAS - Brain Vehicle
Slide 10: Spinal Cord: Efficient Glycogen Reduction with Engineered hGAA
Preclinical Pompe Gene Therapy Results at ASGCT 10 Spinal Cord– 28 days after AAV Gene Therapy Engineered hGAA was able to Reduce Glycogen Efficiently in the Spinal Cord while Little GGlycogenlycogen Luxo lReduction/PAS – Spinal Cwasord Observed for Natural Vehicle AAV.hGAA nat AAV.hGAA eng Wild-Typ
Slide 11: Conclusions
Preclinical Pompe Gene Therapy Results at ASGCT 11 Conclusions • AAV gene therapy expressing the engineered hGAA led to more uniform cellular uptake, glycogen reduction, and resolved cellular dysfunction via efficient cross-correction. • AAV gene therapy expressing the engineered hGAA demonstrated e
Slide 12: Program Status and Anticipated Milestones
Preclinical Pompe Gene Therapy Results at ASGCT 12 Program Status and Anticipated Milestones Initial Findings Validate Amicus/Penn Collaboration Combining Amicus-Engineered Transgenes with Penn’s AAV Gene Therapy Technologies • Pompe AAV gene therapy program builds upon protein engineering and manuf
Slide 13: Thank You
Thank You “Our passion for making a difference unites us” -Amicus Belief Statement
Slide 14: Appendix
Appendix
Slide 15: Quadriceps: Cross-Correction and Glycogen Reduction
Preclinical Pompe Gene Therapy Results at ASGCT 15 Quadriceps – 28 days after AAV Gene Therapy Engineered hGAA was more efficient at cross-correction, indicated by greater cellular uptake, lysosomal targeting, and uniform glycogen reduction. Glycogen PAS - Quadriceps Vehicle AAV.hGAA nat AAV.hGAA en
Slide 16: Triceps: Cross-Correction and Glycogen Reduction
Preclinical Pompe Gene Therapy Results at ASGCT 16 Triceps – 28 days after AAV Gene Therapy Engineered hGAA was more efficient at cross-correction, indicated by greater cellular uptake, lysosomal targeting, and uniform glycogen reduction. Glycogen PAS - Triceps Vehicle AAV.hGAA nat AAV.hGAA eng Wild
Slide 17: Early Proof of Principle for Optimized Gene Therapy
Preclinical Pompe Gene Therapy Results at ASGCT 17 Early Proof of Principle for Optimized Gene Therapy Amicus DNA Constructs Enable Optimized Gene Therapy in Pompe and Fabry GAA Binding to Intended Receptor SecretedS e c re te d GAArh G A Ain i nMedia M e d ia 8 0 0 0 y t 8 0 A m ic u s G T - G A A
Amicus Therapeutics — Technical Presentation (April 2019) on 6ix